User profiles for Ashley Akbari
 | Ashley AkbariProfessor of Population Data Science Research at Swansea University Verified email at swansea.ac.uk Cited by 5044 |
[HTML][HTML] Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study
Background The BNT162b2 mRNA (Pfizer–BioNTech) and ChAdOx1 nCoV-19 (Oxford–AstraZeneca)
COVID-19 vaccines have shown high efficacy against disease in phase 3 clinical …
COVID-19 vaccines have shown high efficacy against disease in phase 3 clinical …
[HTML][HTML] Measuring multimorbidity in research: Delphi consensus study
… Iris SS Ho, 1 Amaya Azcoaga-Lorenzo, 2 Ashley Akbari, 3 Jim Davies, 4 Kamlesh Khunti,
5 Umesh T Kadam, 5 Ronan A Lyons, 6 Colin McCowan, 2 Stewart W Mercer, 1 …
5 Umesh T Kadam, 5 Ronan A Lyons, 6 Colin McCowan, 2 Stewart W Mercer, 1 …
[HTML][HTML] The impact of the COVID-19 pandemic on cardiovascular disease prevention and management
How the Coronavirus Disease 2019 (COVID-19) pandemic has affected prevention and
management of cardiovascular disease (CVD) is not fully understood. In this study, we used …
management of cardiovascular disease (CVD) is not fully understood. In this study, we used …
[HTML][HTML] First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
Reports of ChAdOx1 vaccine–associated thrombocytopenia and vascular adverse events
have led to some countries restricting its use. Using a national prospective cohort, we …
have led to some countries restricting its use. Using a national prospective cohort, we …
[HTML][HTML] Hospitalized prevalence and 5-year mortality for IBD: record linkage study
…, SE Roberts, MJ Goldacre, A Akbari… - World journal of …, 2010 - ncbi.nlm.nih.gov
AIM: To establish the hospitalized prevalence of severe Crohn’s disease (CD) and ulcerative
colitis (UC) in Wales from 1999 to 2007; and to investigate long-term mortality after …
colitis (UC) in Wales from 1999 to 2007; and to investigate long-term mortality after …
[HTML][HTML] Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million …
…, J Oke, L Patterson, C Robertson, A Akbari… - The Lancet, 2022 - thelancet.com
Background Current UK vaccination policy is to offer future COVID-19 booster doses to
individuals at high risk of serious illness from COVID-19, but it is still uncertain which groups of …
individuals at high risk of serious illness from COVID-19, but it is still uncertain which groups of …
Association of COVID-19 with major arterial and venous thrombotic diseases: a population-wide cohort study of 48 million adults in England and Wales
Background: Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
induces a prothrombotic state, but long-term effects of COVID-19 on incidence of vascular …
induces a prothrombotic state, but long-term effects of COVID-19 on incidence of vascular …
[HTML][HTML] COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2· 57 million people in Scotland (EAVE II): a prospective …
Background The UK COVID-19 vaccination programme has prioritised vaccination of those
at the highest risk of COVID-19 mortality and hospitalisation. The programme was rolled out …
at the highest risk of COVID-19 mortality and hospitalisation. The programme was rolled out …
[HTML][HTML] Examining variation in the measurement of multimorbidity in research: a systematic review of 566 studies
ISS Ho, A Azcoaga-Lorenzo, A Akbari… - The Lancet Public …, 2021 - thelancet.com
Background A systematic understanding of how multimorbidity has been constructed and
measured is unavailable. This review aimed to examine the definition and measurement of …
measured is unavailable. This review aimed to examine the definition and measurement of …
[HTML][HTML] Effectiveness of first dose of COVID-19 vaccines against hospital admissions in Scotland: national prospective cohort study of 5.4 million people
Background: The BNT162b2 mRNA (Pfizer-BioNTech) and ChAdOx1 (Oxford-AstraZeneca)
COVID-19 vaccines have demonstrated high efficacy against infection in phase 3 clinical …
COVID-19 vaccines have demonstrated high efficacy against infection in phase 3 clinical …
